Complete remission with ibrutinib after allogeneic stem cell transplant for central nervous system relapse of mantle cell lymphoma: A case report and literature review.

Authors :: Rich JD
Clark SM
Fedoriw Y
Jewells V
Wood W
Dittus C
Source :: Clinical case reports [Clin Case Rep] 2019 Sep 03; Vol. 7 (10), pp. 1957-1961. Date of Electronic Publication: 2019 Sep 03 (Print Publication: 2019).
Publication Year :: 2019
Abstract: Central nervous system (CNS)-relapsed mantle cell lymphoma (MCL) is a rare, aggressive non-Hodgkin lymphoma without a standard treatment. Ibrutinib has shown promising results for inducing remission in other non-Hodgkin lymphomas and may be considered as successful treatment for CNS-relapsed MCL in the future as well.<br />Competing Interests: None declared.<br /> (© 2019 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.)

Full Text Access

Tools